Impact of minocycline on outcomes of EGFR-mutant non-small cell lung cancer patients treated with EGFR-TKIs

Minocycline is often administered prophylactically or therapeutically to non-small cell lung cancer (NSCLC) patients receiving epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) for skin rash as an adverse event. We examined the effects of minocycline on the outcomes of EGFR-mut...

Descripción completa

Detalles Bibliográficos
Autores principales: Tone, Mari, Iwahori, Kota, Shiroyama, Takayuki, Futami, Shinji, Naito, Yujiro, Fukushima, Kiyoharu, Miyake, Kotaro, Koyama, Shohei, Hirata, Haruhiko, Nagatomo, Izumi, Wada, Hisashi, Takeda, Yoshito, Kumanogoh, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204024/
https://www.ncbi.nlm.nih.gov/pubmed/37221285
http://dx.doi.org/10.1038/s41598-023-35519-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204024/
https://www.ncbi.nlm.nih.gov/pubmed/37221285
http://dx.doi.org/10.1038/s41598-023-35519-4

Ejemplares similares